Figure 7: Reduced increase in P-Erk1/2 levels in MEFs transformed with KrasG13D,C118S upon EGF treatment. | Nature Communications

Figure 7: Reduced increase in P-Erk1/2 levels in MEFs transformed with KrasG13D,C118S upon EGF treatment.

From: Decreased tumorigenesis in mice with a Kras point mutation at C118

Figure 7

Immunoblot of Flag-tagged ectopic Kras, tubulin, as well as total (T) and phosphorylated (P) Erk1/2 from (a) KrasC118S/C118S or (c) Nras−/−;Hras−/−;KrasC118S/C118S MEFs immortalized with the SV40 early region and transformed with either Flag-KrasG13D or Flag-KrasG13D,C118S in the absence or presence of EGF stimulation. (b,d) Mean±s.e.m. of P-Erk1/2 levels (normalized to T-Erk1/2) from three independent experiments using lysates from (b) KrasC118S/C118S or (d) Nras−/−;Hras−/−;KrasC118S/C118S MEFs immortalized with the SV40 early region and transformed with either Flag-KrasG13D or Flag-KrasG13D,C118S in the absence or presence of EGF stimulation. NS: non-significant (P>0.05). *P<0.05, as determined using one-way analysis of variance plus post-hoc Bonferroni’s multiple comparison test.

Back to article page